Careers  |  Sign In  |  Register  |   Twitter

Gilead Hepatitis C Drug Will Be Made Cheaper in Low-Income Nations

Sovaldi, Gilead Sciences Inc.‘s hepatitis C drug which currently costs $1,000 per pill, will be available in 91 developing nations at a lower cost, Reuters article reports. Roughly 150 million people in the world have chronic hepatitis C; few of them have access to the treatment they need. Normally, the 12-week treatment plan costs $84,000 in the U.S., though the company has announced that it will offer the medicine in Egypt at a 99 percent discount, as well as a branded launch in India that will cost patients $300 per month. Nevertheless, Sovaldi is set to exceed $11 billion in sales this year.

Read the article published by Reuters.